GcgR Monoclonal Antibody Administration Protocol

Hyperglycemic (blood glucose concentration 275–400 mg/dL) db/db mice matched for blood glucose level were randomized to receive either a single weekly injection (5 mg/kg BW s.c.) of monoclonal antibody (mAb) B (a fully human GcgR mAb developed by REMD Biotherapeutics, Inc., Camarillo, CA) (6,27) or vehicle. The vehicle-treated group was further divided into an ad libitum fed group or a pair-fed group, in which they were given an amount of food daily that matched the daily food intake of the mAb-administered mice. Blood glucose and plasma ghrelin levels were measured at 9 weeks of age, 5 days after the last weekly injection, at 10:00 a.m.

The Ghsr-null mice were administered STZ (150 mg/kg i.p.) and then treated with a single injection of mAb B (10 mg/kg s.c.) or vehicle when the blood glucose concentration reached between 275 and 450 mg/dL. Blood glucose levels were measured 4 days after treatment at 10:00 a.m. and again 1 day later after a 24-h fast.